person · Reporting owner

MIZELL STEVEN

Disclosed activity across 6 companies

Tapewire entity: 11446
SEC CIK: 0001189403

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Allegion plcALLE · Entity 3420	Director	August 28, 2026	August 31, 2026
GRAIL, Inc.GRAL · Entity 4122	Director	July 15, 2026	July 16, 2026
GROUP 1 AUTOMOTIVE INCGPI · Entity 1789	Director	January 02, 2026	January 06, 2026
Merck & Co., Inc.MRK · Entity 2807	EVP, Chief HR Officer	February 02, 2024	February 02, 2024
OSHKOSH CORPOSK · Entity 3573	Director	November 19, 2018	November 21, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Allegion plc

Report date August 28, 2026 · Filed August 31, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	5,899	Reported balance After 2026-08-28 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-08-28 · Purchase · Acquired 170 · Balance 5,899 F1: Includes shares acquired through a dividend reinvestment plan since the Reporting Person's last Form 4 filing.

Filing footnotes · ownership attribution and instrument terms

F1: Includes shares acquired through a dividend reinvestment plan since the Reporting Person's last Form 4 filing.

GRAIL, Inc.

Report date July 15, 2026 · Filed July 16, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	42,830	Reported balance After 2026-07-15 transaction · row 1 1 source row Row 1 · 2026-07-15 · Grant · Acquired 268 · Balance 42,830 F1: Represents 268 deferred stock units granted to Mr. Mizell under our deferred stock program and 2024 Equity Incentive Plan in lieu of $19,945.21 of cash fees payable to Mr. Mizell for his service as a director, based on a price per share of $74.36, which was the closing price per share of the Company's common stock on July 15, 2026. The awards will vest immediately upon grant date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents 268 deferred stock units granted to Mr. Mizell under our deferred stock program and 2024 Equity Incentive Plan in lieu of $19,945.21 of cash fees payable to Mr. Mizell for his service as a director, based on a price per share of $74.36, which was the closing price per share of the Company's common stock on July 15, 2026. The awards will vest immediately upon grant date.

GROUP 1 AUTOMOTIVE INC

Report date January 02, 2026 · Filed January 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	583	Reported balance After 2026-01-02 transaction · row 1 1 source row Row 1 · 2026-01-02 · Grant · Acquired 575 · Balance 583

Merck & Co., Inc.

Report date February 02, 2024 · Filed February 02, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	23,619.145	Ending reported balance After 2024-02-02 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2024-02-02 · Exercise / conversion · Acquired 824 · Balance 42,143.145 Row 2 · 2024-02-02 · Exercise / conversion · Acquired 32,170 · Balance 74,313.145 Row 3 · 2024-02-02 · Sale · Disposed 50,694 · Balance 23,619.145 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.4300 to $126.9000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.71 · Expires 2028-10-29	Direct	0	Reported balance After 2024-02-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-02-02 · Exercise / conversion · Disposed 824 · Balance 0 F2: The option vested and became exercisable in three equal installments on 10/30/2019, 10/30/2020 and 10/30/2021.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $73.73 · Expires 2031-05-03	Direct	22,088	Reported balance After 2024-02-02 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-02-02 · Exercise / conversion · Disposed 32,170 · Balance 22,088 F3: The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.4300 to $126.9000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The option vested and became exercisable in three equal installments on 10/30/2019, 10/30/2020 and 10/30/2021.

F3: The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.

OSHKOSH CORP

Report date November 19, 2018 · Filed November 21, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	11,660.31	Reported balance After 2018-11-19 transaction · row 1 1 source row Row 1 · 2018-11-19 · Grant · Acquired 47.34 · Balance 11,660.31 F1: Represents stock units payable in Oshkosh Corporation common stock acquired in accordance with the dividend reinvestment feature of the Oshkosh Corporation Deferred Compensation Plan for Directors and Executive Officers.

Filing footnotes · ownership attribution and instrument terms

F1: Represents stock units payable in Oshkosh Corporation common stock acquired in accordance with the dividend reinvestment feature of the Oshkosh Corporation Deferred Compensation Plan for Directors and Executive Officers.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

MONSANTO CO /NEW/

Report date June 07, 2018 · Filed June 07, 2018

Section 16 reporting ended · disclosed 2018-06-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-06-07 transaction · row 1 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 1 · 2018-06-07 · Disposition to issuer · Disposed 62 · Balance 0 F1: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-06-07 transaction · row 3 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 3 · 2018-06-07 · Disposition to issuer · Disposed 48,581 · Balance 0 F4: Represents restricted stock units. F1: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-06-07 transaction · row 4 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 4 · 2018-06-07 · Disposition to issuer · Disposed 19,787 · Balance 0 F5: Represents performance-based restricted stock units. F1: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate.
Common StockSEC Table I · non-derivative	IndirectBy 401(k) Plan	Reported balance After 2018-06-07 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2018-06-07 · Disposition to issuer · Disposed 1,024 · Balance 0 F1: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.71	Direct	Reported balance After 2018-06-07 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-06-07 · Disposition to issuer · Disposed 7 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $74.79	Direct	Reported balance After 2018-06-07 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-06-07 · Disposition to issuer · Disposed 70 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $90.48	Direct	Reported balance After 2018-06-07 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-06-07 · Disposition to issuer · Disposed 91 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $106.05	Direct	Reported balance After 2018-06-07 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2018-06-07 · Disposition to issuer · Disposed 80 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $112.82	Direct	Reported balance After 2018-06-07 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2018-06-07 · Disposition to issuer · Disposed 5,764 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $91.34	Direct	Reported balance After 2018-06-07 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2018-06-07 · Disposition to issuer · Disposed 7,234 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest.
Deferred Payment Plan Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2018-06-07 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2018-06-07 · Disposition to issuer · Disposed 1,926 · Balance 0 F1: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate.
Phantom Share UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2018-06-07 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2018-06-07 · Disposition to issuer · Disposed 16,473 · Balance 0 F1: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration").

F2: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate.

F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest.

F4: Represents restricted stock units.

F5: Represents performance-based restricted stock units.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 28, 2026 Filed Aug 31, 2026 17:54 UTC	Allegion plc ALLE · Entity 3420	PurchaseOrdinary Shares	170	$158.28	$26,907.60	Disclosure SEC source: 0001189403-26-000011 · wk-form4_1788198882.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,899 F1 · balance_after: Includes shares acquired through a dividend reinvestment plan since the Reporting Person's last Form 4 filing. Read SEC document
July 15, 2026 Filed Jul 16, 2026 20:43 UTC	GRAIL, Inc. GRAL · Entity 4122	GrantCommon Stock	268	$74.36	$19,928.48	Disclosure SEC source: 0001628280-26-048486 · wk-form4_1784234617.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,830 F1 · shares: Represents 268 deferred stock units granted to Mr. Mizell under our deferred stock program and 2024 Equity Incentive Plan in lieu of $19,945.21 of cash fees payable to Mr. Mizell for his service as a director, based on a price per share of $74.36, which was the closing price per share of the Company's common stock on July 15, 2026. The awards will vest immediately upon grant date. Read SEC document
June 18, 2026 Filed Jun 22, 2026 21:30 UTC	GRAIL, Inc. GRAL · Entity 4122	GrantCommon Stock	5,491	$63.74	$349,996.34	Disclosure SEC source: 0001628280-26-044735 · wk-form4_1782163811.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,562 F1 · shares: Represents an award of 5,491 deferred stock units ("DSUs") granted to Mr. Mizell under our 2024 Equity Incentive Plan in lieu of 5,491 restricted stock units. The DSUs will vest in full on the earlier to occur of (i) June 18, 2027 and (ii) the date of the next annual meeting of the Company's stockholders, in each case subject to continued service through the applicable vesting date. Each DSU represents the right to receive, at settlement, one share of common stock. Read SEC document
June 05, 2026 Filed Jun 9, 2026 18:34 UTC	Allegion plc ALLE · Entity 3420	Tax withholdingOrdinary Shares	292	$130.27	$38,038.84	Disclosure SEC source: 0001189403-26-000009 · wk-form4_1781030078.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,711 F1 · shares: Represents shares withheld by the Issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. Read SEC document
June 04, 2026 Filed Jun 8, 2026 19:25 UTC	Allegion plc ALLE · Entity 3420	GrantOrdinary Shares	1,074	$0.00	$0.00	Disclosure SEC source: 0001189403-26-000006 · wk-form4_1780946717.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,003 F1 · shares: Restricted stock units that vest on June 4, 2027. F2 · balance_after: Includes shares acquired through a dividend reinvestment plan since the reporting person's last Form 4 filing. Read SEC document
April 15, 2026 Filed Apr 17, 2026 20:07 UTC	GRAIL, Inc. GRAL · Entity 4122	GrantCommon Stock	396	$49.79	$19,716.84	Disclosure SEC source: 0001628280-26-025731 · wk-form4_1776456426.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,071 F1 · shares: Represents 396 deferred stock units granted to Mr. Mizell under our deferred stock program and 2024 Incentive Award Plan in lieu of $19,726.03 of cash fees payable to Mr. Mizell for his service as a director, based on a price per share of $49.79, which was the closing price per share of the Company's common stock on April 15, 2026. The awards will vest immediately upon grant date. Read SEC document
February 19, 2026 Filed Feb 20, 2026 19:08 UTC	Allegion plc ALLE · Entity 3420	SaleOrdinary Shares	1,000	$161.51	$161,510.00	Disclosure SEC source: 0001189403-26-000003 · wk-form4_1771614500.xml · nonDerivative · entry 2 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,915 F2 · price: This transaction was executed in multiple sales ranging from $161.50 to $161.59 per share, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer, or any security holder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
February 18, 2026 Filed Feb 20, 2026 19:08 UTC	Allegion plc ALLE · Entity 3420	SaleOrdinary Shares	400	$163.79	$65,516.00	Disclosure SEC source: 0001189403-26-000003 · wk-form4_1771614500.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,915 F1 · balance_after: Includes shares acquired through a dividend reinvestment plan since the reporting person's last Form 4 filing. Read SEC document
January 15, 2026 Filed Jan 16, 2026 21:55 UTC	GRAIL, Inc. GRAL · Entity 4122	GrantCommon Stock	206	$97.44	$20,072.64	Disclosure SEC source: 0001628280-26-002426 · wk-form4_1768600539.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,675 F1 · shares: Represents 206 deferred stock units granted to Mr. Mizell under our deferred stock program and 2024 Incentive Award Plan in lieu of $20,164.38 of cash fees payable to Mr. Mizell for his service as a director, based on a price per share of $97.44, which was the closing price per share of the Company's common stock on January 15, 2026. The awards will vest immediately upon grant date. Read SEC document
January 02, 2026 Filed Jan 6, 2026 23:12 UTC	GROUP 1 AUTOMOTIVE INC GPI · Entity 1789	GrantCommon Stock	575	$0.00	$0.00	Disclosure SEC source: 0001031203-26-000026 · form4.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 583 Read SEC document
October 15, 2025 Filed Oct 16, 2025 22:17 UTC	GRAIL, Inc. GRAL · Entity 4122	GrantCommon Stock	267	$75.52	$20,163.84	Disclosure SEC source: 0001628280-25-045268 · wk-form4_1760653073.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,469 F1 · shares: Represents 267 deferred stock units granted to Mr. Mizell under our deferred stock program and 2024 Equity Incentive Plan in lieu of $20,164.38 of cash fees payable to Mr. Mizell for his service as a director, based on a price per share of $75.52, which was the closing price per share of the Company's common stock on October 15, 2025. The awards will vest immediately upon grant date. Read SEC document
July 29, 2025 Filed Jul 30, 2025 20:39 UTC	GROUP 1 AUTOMOTIVE INC GPI · Entity 1789	SaleCommon Stock	525	$417.98	$219,439.50	Disclosure SEC source: 0001127602-25-019766 · form4.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8 Read SEC document
July 15, 2025 Filed Jul 17, 2025 21:45 UTC	GRAIL, Inc. GRAL · Entity 4122	GrantCommon Stock	517	$38.53	$19,920.01	Disclosure SEC source: 0001699031-25-000154 · wk-form4_1752788728.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,202 F1 · acquired: Represents 517 deferred stock units granted to Mr. Mizell under our deferred stock program and 2024 Equity Incentive Plan in lieu of $19,945.21 of cash fees payable to Mr. Mizell for his service as a director, based on a price per share of $38.53, which was the closing price per share of the Company's common stock on July 15, 2025. The awards will vest immediately upon grant date. Read SEC document
June 06, 2025 Filed Jun 10, 2025 21:24 UTC	Allegion plc ALLE · Entity 3420	Tax withholdingOrdinary Shares	319	$139.34	$44,449.46	Disclosure SEC source: 0001127602-25-017240 · form4.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,275 F1 · shares: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. Read SEC document
June 05, 2025 Filed Jun 9, 2025 21:00 UTC	Allegion plc ALLE · Entity 3420	GrantOrdinary Shares	1,013	$0.00	$0.00	Disclosure SEC source: 0001127602-25-017108 · form4.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,594 F1 · shares: Restricted stock units that vest on June 5, 2026. F2 · balance_after: Includes acquisition of shares through a dividend reinvestment plan. Read SEC document
May 29, 2025 Filed May 30, 2025 23:22 UTC	GRAIL, Inc. GRAL · Entity 4122	GrantCommon Stock	6,082	$41.10	$249,970.20	Disclosure SEC source: 0001699031-25-000128 · wk-form4_1748647344.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,685 F1 · shares: Represents an award of 6,082 deferred stock units ("DSUs") granted to Mr. Mizell under our 2024 Equity Incentive Plan in lieu of 6,082 restricted stock units. The DSUs will vest in full on the earlier to occur of (i) May 29, 2026 and (ii) the date of the next annual meeting of the Company's stockholders, in each case subject to continued service through the applicable vesting date. Each DSU represents the right to receive, at settlement, one share of common stock. Read SEC document
April 15, 2025 Filed Apr 16, 2025 22:32 UTC	GRAIL, Inc. GRAL · Entity 4122	GrantCommon Stock	760	$25.94	$19,714.40	Disclosure SEC source: 0001699031-25-000082 · wk-form4_1744842767.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,603 F1 · shares: Represents 760 deferred stock units granted to Mr. Mizell under our deferred stock program and 2024 Equity Incentive Plan in lieu of $19,726.03 of cash fees payable to Mr. Mizell for his service as a director, based on a price per share of $25.94, which was the closing price per share of the Company's common stock on April 15, 2025. The awards will vest immediately upon grant date. Read SEC document
January 15, 2025 Filed Jan 16, 2025 21:52 UTC	GRAIL, Inc. GRAL · Entity 4122	GrantCommon Stock	1,147	$17.58	$20,164.26	Disclosure SEC source: 0001628280-25-001745 · wk-form4_1737064352.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,843 F1 · shares: Represents 1,147 deferred stock units granted to Mr. Mizell under our deferred stock program and 2024 Equity Incentive Plan in lieu of $20,164.38 of cash fees payable to Mr. Mizell for his service as a director, based on a price per share of $17.58, which was the closing price per share of the Company's common stock on January 15, 2025. The awards will vest immediately upon grant date. Read SEC document
January 02, 2025 Filed Jan 6, 2025 19:32 UTC	GROUP 1 AUTOMOTIVE INC GPI · Entity 1789	GrantCommon Stock	533	$0.00	$0.00	Disclosure SEC source: 0001127602-25-000673 · form4.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 533 Read SEC document
October 30, 2024 Filed Nov 1, 2024 22:16 UTC	GRAIL, Inc. GRAL · Entity 4122	GrantCommon Stock	248	$13.62	$3,377.76	Disclosure SEC source: 0001628280-24-044797 · wk-form4_1730499396.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,696 F1 · price: Represents 248 deferred stock units granted to Mr. Mizell under our deferred stock program and 2024 Equity Incentive Plan in lieu of $3,383.56 of cash fees payable to Mr. Mizell for his service as a director, based on a price per share of $13.62, which was the closing price per share of the Company's common stock on October 30, 2024. The awards will vest immediately upon grant date. Read SEC document
October 15, 2024 Filed Oct 17, 2024 22:35 UTC	GRAIL, Inc. GRAL · Entity 4122	GrantCommon Stock	978	$14.01	$13,701.78	Disclosure SEC source: 0001628280-24-043073 · wk-form4_1729204505.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,448 F1 · shares: Represents 978 deferred stock units granted to Mr. Mizell under our deferred stock program and 2024 Equity Incentive Plan in lieu of $13,712.33 of cash fees payable to Mr. Mizell for his service as a director, based on a price per share of $14.01, which was the closing price per share of the Company's common stock on October 15, 2024. The awards will vest immediately upon grant date. Read SEC document
July 26, 2024 Filed Jul 30, 2024 20:20 UTC	Allegion plc ALLE · Entity 3420	PurchaseOrdinary Shares	1,000	$136.53	$136,529.70	Disclosure SEC source: 0001127602-24-021166 · form4.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,545 F1 · balance_after: Includes acquisition of shares through a dividend reinvestment plan. Read SEC document
June 25, 2024 Filed Jun 27, 2024 21:14 UTC	GRAIL, Inc. GRAL · Entity 4122	GrantCommon Stock	26,470	$0.00	$0.00	Disclosure SEC source: 0001628280-24-030364 · wk-form4_1719522861.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,470 F1 · shares: Represents an award of 26,470 restricted stock units ("RSUs") which will vest and become payable in three substantially equal annual installments beginning on June 21, 2025, subject to full accelerated vesting upon a change in control of the Issuer. Each RSU represents the right to receive, at settlement, one share of common stock. The RSUs will be settled in common stock upon vesting. Read SEC document
June 08, 2024 Filed Jun 11, 2024 20:23 UTC	Allegion plc ALLE · Entity 3420	Tax withholdingOrdinary Shares	294	$116.52	$34,256.88	Disclosure SEC source: 0001127602-24-018366 · form4.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,532 F1 · shares: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. Read SEC document
June 06, 2024 Filed Jun 10, 2024 23:18 UTC	Allegion plc ALLE · Entity 3420	GrantOrdinary Shares	1,105	$0.00	$0.00	Disclosure SEC source: 0001127602-24-018308 · form4.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,826 F1 · shares: Restricted stock units that vest on June 6, 2025. F2 · balance_after: Includes acquisition of shares through a dividend reinvestment plan. Read SEC document
February 02, 2024 Filed Feb 2, 2024 21:07 UTC	Merck & Co., Inc. MRK · Entity 2807	Exercise / conversionStock Option (Right to Buy) · Derivative	32,170	$0.00 Strike: $73.73	$0.00	Disclosure SEC source: 0001127602-24-003099 · form4.xml · derivative · entry 5 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,088 Underlying: Common Stock · 32,170 shares Expires 2031-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. Read SEC document
February 02, 2024 Filed Feb 2, 2024 21:07 UTC	Merck & Co., Inc. MRK · Entity 2807	Exercise / conversionStock Option (Right to Buy) · Derivative	824	$0.00 Strike: $70.71	$0.00	Disclosure SEC source: 0001127602-24-003099 · form4.xml · derivative · entry 4 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 824 shares Expires 2028-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested and became exercisable in three equal installments on 10/30/2019, 10/30/2020 and 10/30/2021. Read SEC document
February 02, 2024 Filed Feb 2, 2024 21:07 UTC	Merck & Co., Inc. MRK · Entity 2807	SaleCommon Stock	50,694	$126.65	$6,420,349.48	Disclosure SEC source: 0001127602-24-003099 · form4.xml · nonDerivative · entry 3 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,619.145 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.4300 to $126.9000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
February 02, 2024 Filed Feb 2, 2024 21:07 UTC	Merck & Co., Inc. MRK · Entity 2807	Exercise / conversionCommon Stock	32,170	$73.73	$2,371,894.10	Disclosure SEC source: 0001127602-24-003099 · form4.xml · nonDerivative · entry 2 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,313.145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 02, 2024 Filed Feb 2, 2024 21:07 UTC	Merck & Co., Inc. MRK · Entity 2807	Exercise / conversionCommon Stock	824	$70.71	$58,265.04	Disclosure SEC source: 0001127602-24-003099 · form4.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,143.145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 22, 2024 Filed Jan 24, 2024 21:13 UTC	Merck & Co., Inc. MRK · Entity 2807	GrantCommon Stock	18,384	$119.43	$2,195,601.12	Disclosure SEC source: 0001127602-24-002029 · form4.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,319.145 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/21. Performance shares were paid out at 161 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2023. Read SEC document
January 02, 2024 Filed Jan 4, 2024 18:01 UTC	GROUP 1 AUTOMOTIVE INC GPI · Entity 1789	GrantRestricted Stock Units · Derivative	739	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-24-000742 · form4.xml · derivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,940 Underlying: Common Stock · 739 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive the cash value of one share of Group 1 Automotive, Inc. common stock. F2 · derivative.exercise_date: The restricted stock units settle on the date of the director's separation from service, as such term is defined in Section 1.409A-1(h) under Title 26 of the Internal Revenue Code, and will be settled in a lump sum cash payment. F2 · derivative.expiration_date: The restricted stock units settle on the date of the director's separation from service, as such term is defined in Section 1.409A-1(h) under Title 26 of the Internal Revenue Code, and will be settled in a lump sum cash payment. Read SEC document
December 08, 2023 Filed Dec 12, 2023 22:21 UTC	Allegion plc ALLE · Entity 3420	Tax withholdingOrdinary Shares	86	$109.51	$9,417.43	Disclosure SEC source: 0001127602-23-029456 · form4.xml · nonDerivative · entry 2 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,703 F1 · shares: Cancellation of 86 shares for the payment of taxes upon the issuance of shares on December 8, 2023. F2 · balance_after: Includes acquisition of shares through a dividend reinvestment plan. Read SEC document
December 08, 2023 Filed Dec 12, 2023 22:21 UTC	Allegion plc ALLE · Entity 3420	GrantOrdinary Shares	298	$0.00	$0.00	Disclosure SEC source: 0001127602-23-029456 · form4.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,789 Read SEC document
August 14, 2023 Filed Aug 15, 2023 20:08 UTC	Merck & Co., Inc. MRK · Entity 2807	SaleCommon Stock	4,250	$109.01	$463,292.50	Disclosure SEC source: 0001127602-23-022547 · form4.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,935.145 Read SEC document
August 03, 2023 Filed Aug 4, 2023 20:06 UTC	Merck & Co., Inc. MRK · Entity 2807	SaleCommon Stock	4,500	$105.49	$474,700.95	Disclosure SEC source: 0001127602-23-022002 · form4.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,185.145 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.4800 to $105.4900, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document
June 08, 2023 Filed Jun 12, 2023 20:28 UTC	Allegion plc ALLE · Entity 3420	GrantOrdinary Shares	1,019	$0.00	$0.00	Disclosure SEC source: 0001127602-23-018559 · form4.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,472 F1 · shares: Restricted stock units that vest on June 8, 2024. Read SEC document
June 02, 2023 Filed Jun 6, 2023 20:20 UTC	Allegion plc ALLE · Entity 3420	Tax withholdingOrdinary Shares	293	$107.41	$31,471.13	Disclosure SEC source: 0001127602-23-018041 · form4.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,453 F1 · balance_after: Includes acquisition of shares through a dividend reinvestment plan. Read SEC document
May 03, 2023 Filed May 5, 2023 21:19 UTC	Merck & Co., Inc. MRK · Entity 2807	Exercise / conversionStock Option (Right to Buy) · Derivative	12,000	$0.00 Strike: $75.36	$0.00	Disclosure SEC source: 0001127602-23-014764 · form4.xml · derivative · entry 12 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,151 Underlying: Common Stock · 12,000 shares Expires 2030-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F8 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document
May 03, 2023 Filed May 5, 2023 21:19 UTC	Merck & Co., Inc. MRK · Entity 2807	Exercise / conversionStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $75.36	$0.00	Disclosure SEC source: 0001127602-23-014764 · form4.xml · derivative · entry 11 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,151 Underlying: Common Stock · 15,000 shares Expires 2030-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F8 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document
May 03, 2023 Filed May 5, 2023 21:19 UTC	Merck & Co., Inc. MRK · Entity 2807	Exercise / conversionStock Option (Right to Buy) · Derivative	12,000	$0.00 Strike: $73.73	$0.00	Disclosure SEC source: 0001127602-23-014764 · form4.xml · derivative · entry 10 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,258 Underlying: Common Stock · 12,000 shares Expires 2031-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F7 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. Read SEC document
May 03, 2023 Filed May 5, 2023 21:19 UTC	Merck & Co., Inc. MRK · Entity 2807	Exercise / conversionStock Option (Right to Buy) · Derivative	13,000	$0.00 Strike: $77.62	$0.00	Disclosure SEC source: 0001127602-23-014764 · form4.xml · derivative · entry 9 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,366 Underlying: Common Stock · 13,000 shares Expires 2029-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F6 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022. Read SEC document
May 03, 2023 Filed May 5, 2023 21:19 UTC	Merck & Co., Inc. MRK · Entity 2807	SaleCommon Stock	13,400	$119.01	$1,594,734.00	Disclosure SEC source: 0001127602-23-014764 · form4.xml · nonDerivative · entry 8 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,685.145 Read SEC document
May 03, 2023 Filed May 5, 2023 21:19 UTC	Merck & Co., Inc. MRK · Entity 2807	Exercise / conversionCommon Stock	12,000	$75.36	$904,320.00	Disclosure SEC source: 0001127602-23-014764 · form4.xml · nonDerivative · entry 7 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,085.145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 03, 2023 Filed May 5, 2023 21:19 UTC	Merck & Co., Inc. MRK · Entity 2807	SaleCommon Stock	12,000	$119.01	$1,428,088.80	Disclosure SEC source: 0001127602-23-014764 · form4.xml · nonDerivative · entry 6 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,085.145 F1 · kind: These exercise and sale transactions were made pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.0000 to $119.0800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document
May 03, 2023 Filed May 5, 2023 21:19 UTC	Merck & Co., Inc. MRK · Entity 2807	SaleCommon Stock	15,000	$119.01	$1,785,121.50	Disclosure SEC source: 0001127602-23-014764 · form4.xml · nonDerivative · entry 5 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,085.145 F1 · kind: These exercise and sale transactions were made pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.0000 to $119.0600, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document
May 03, 2023 Filed May 5, 2023 21:19 UTC	Merck & Co., Inc. MRK · Entity 2807	SaleCommon Stock	13,000	$119.01	$1,547,111.80	Disclosure SEC source: 0001127602-23-014764 · form4.xml · nonDerivative · entry 4 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,085.145 F1 · kind: These exercise and sale transactions were made pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.0000 to $119.1300, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document
May 03, 2023 Filed May 5, 2023 21:19 UTC	Merck & Co., Inc. MRK · Entity 2807	Exercise / conversionCommon Stock	12,000	$73.73	$884,760.00	Disclosure SEC source: 0001127602-23-014764 · form4.xml · nonDerivative · entry 3 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,085.145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercise and sale transactions were made pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2023. Read SEC document
May 03, 2023 Filed May 5, 2023 21:19 UTC	Merck & Co., Inc. MRK · Entity 2807	Exercise / conversionCommon Stock	15,000	$75.36	$1,130,400.00	Disclosure SEC source: 0001127602-23-014764 · form4.xml · nonDerivative · entry 2 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,085.145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercise and sale transactions were made pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2023. Read SEC document
May 03, 2023 Filed May 5, 2023 21:19 UTC	Merck & Co., Inc. MRK · Entity 2807	Exercise / conversionCommon Stock	13,000	$77.62	$1,009,060.00	Disclosure SEC source: 0001127602-23-014764 · form4.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,085.145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercise and sale transactions were made pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2023. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.